Low baseline CD4 count and delay in CKD diagnosis (biological assessment only every 6 months) may have contributed to an increased mortality in our most fragile kidney patients, before eventual confirmation of the chronicity of their kidney disease. This evidence concerns the gene CD4 and urogenital neoplasm.